Top in rheumatology: Black box warning on JAK inhibitors, NIH study on COVID-19 boosters
Click Here to Manage Email Alerts
A recent safety review of janus kinase inhibitors revealed that the medications were linked to an increased risk for serious heart-related events, cancer, blood clots and death.
In light of the findings, the FDA announced that it is requiring additional warning labels for the medications. It was the top story in rheumatology last week.
Another top story was about a new trial launched by the NIH that will examine COVID-19 vaccine booster shots in patients with autoimmune disease.
Read these and more top stories in rheumatology below:
FDA adds black box warning to JAK inhibitors; cites heart-related issues, cancer, death
The FDA has called for additional warning labels on janus kinase inhibitors after a safety review found this class of medications was associated with an excess risk for serious heart-related events, cancer, blood clots and death. Read more.
NIH opens study of COVID-19 vaccine booster in patients with autoimmune disease
The NIH has launched a clinical trial to examine antibody responses to a COVID-19 vaccine booster dose in patients with autoimmune disease who failed to respond to the initial vaccine regimen. Read more.
Dysfunctional red blood cells in children may be 'root cause' of lupus
The presence of mature red blood cells that still contain mitochondria is associated with higher systemic lupus erythematosus disease activity, according to data published in Cell. Read more.
Long-term TNF inhibitor use in rheumatoid arthritis not linked to increased cancer risk
There is no increased risk for cancer overall associated with the long-term use of TNF inhibitors for rheumatoid arthritis, according to data published in Rheumatology. Read more.
IVIG boosts platelet counts in COVID-vaccine-induced thrombotic thrombocytopenia
In a case study of three patients with COVID-19 vaccine-induced immune thrombotic thrombocytopenia, starting intravenous immune globulin was linked to reduced antibody-induced platelet activation in serum, according to data. Read more.